Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from its allergen chamber clinical methods trial of topical ocular reproxalap in patients with allergic conjunctivitis and to announce the design of the Phase 3 INVIGORATE clinical trial. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. A live